Sector News

After strong Q3, no $55B deals in AbbVie’s future, CEO says. But a smaller one? Maybe

October 31, 2014
Life sciences
No Shire? No problem for AbbVie. At least, for now.
 
The Illinois drugmaker’s top dog, Humira, is still churning out forecast-topping sales, and it will be for the foreseeable future, the company said Friday. Following a 17.5% global sales leap for the world’s best-selling drug–which has been posting double-digit growth numbers ever since the company spun off from parent Abbott Laboratories early last year–AbbVie now predicts an EPS range of $3.25 to $3.27 for 2014, up from $3.06 to $3.16. 
 
But with a 2016 patent expiration date and biosimilars makers already taking aim, Humira won’t last forever, which was one reason the company this summer agreed to buy Irish drugmaker Shire ($SHPG) for $55 billion–or so industry-watchers thought. Following new U.S. rules that tightened the reins on tax inversions, AbbVie pulled the plug on the deal.
 
And going forward, investors shouldn’t expect a repeat, CEO Richard Gonzalez said on a call with investors. With a Q3 EPS increase of 8.5% and revenue jump of 7.8%–as well as some significant growth prospects on the horizon, like a hep C combo AbbVie expects to launch this year–the company is “in an even stronger position today than before we announced the Shire deal.”
 
“What I don’t think is that we absolutely have an imperative to run out and do another $50 billion deal, and it’s unlikely we would do another $50 billion deal,” he said.
 
On the other hand, considering the company’s cash buildup, “we clearly have the wherewithal to be active on the M&A front,” Gonzalez said–assuming the right target comes along.
 
“We’re going to continue to look for those opportunities that strategically fit and give us a strong financial return,” he said, “and we’ll deploy our capital accordingly.”
 
By Carly Helfand
 

comments closed

Related News

April 26, 2024

Former Bristol Myers CEO tapped as Novartis’ next board chair

Life sciences

Giovanni Caforio, the former CEO of Bristol Myers Squibb, is set to become the next board chairman of Novartis, which on Tuesday proposed the pharmaceutical industry veteran as its pick to replace Joerg Reinhardt in the role next year. Reinhardt has served as Novartis’ chair since 2013 and plans to retire when his 12-year term ends in 2025.

April 26, 2024

GE HealthCare launches voice-activated, AI-powered ultrasound machines for women’s health

Life sciences

GE HealthCare has raised the curtain on two ultrasound systems equipped with artificial intelligence programs designed to assist in diagnosing conditions in women’s health, including obstetric exams. The Voluson Signature 20 and 18 imaging systems include AI tools capable of automatically identifying and annotating measurements of fetal anatomy.

April 26, 2024

Scientists reveal new method that could reduce waste from drug manufacturing

Life sciences

Scientists from the University of Edinburgh’s School of Chemistry have revealed a new sustainable method of manufacturing complex molecules that could reduce waste produced during drug production. The method published in Nature Chemistry could help to prevent severe side effects caused by drugs that can exist as enantiomers.

How can we help you?

We're easy to reach